Vivo Bio Tech Ltd
₹ 24.0
-0.12%
19 Jun
11:38 a.m.
About
Incorporated in 1987, Vivo Bio Tech
Ltd is engaged in service of CRO offering
Drug Development & Discovery Services
to Pharmaceutical & Biotech Companies[1]
Key Points
- Market Cap ₹ 53.3 Cr.
- Current Price ₹ 24.0
- High / Low ₹ 43.4 / 20.4
- Stock P/E
- Book Value ₹ 42.0
- Dividend Yield 0.00 %
- ROCE 7.29 %
- ROE -2.00 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.57 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.59% over past five years.
- Promoter holding is low: 35.4%
- Company has a low return on equity of 2.24% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.65%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.79 | 28.58 | 34.13 | 47.00 | 55.83 | 55.35 | 51.78 | 51.39 | 52.23 | 45.45 | 46.67 | 53.33 | |
| 14.99 | 24.87 | 26.51 | 36.11 | 46.32 | 42.88 | 33.98 | 35.30 | 30.39 | 24.19 | 26.11 | 32.48 | |
| Operating Profit | 2.80 | 3.71 | 7.62 | 10.89 | 9.51 | 12.47 | 17.80 | 16.09 | 21.84 | 21.26 | 20.56 | 20.85 |
| OPM % | 15.74% | 12.98% | 22.33% | 23.17% | 17.03% | 22.53% | 34.38% | 31.31% | 41.82% | 46.78% | 44.05% | 39.10% |
| 0.95 | 0.89 | 0.40 | 0.13 | 0.01 | 0.05 | 0.08 | 0.10 | 0.04 | 0.04 | 4.80 | 0.44 | |
| Interest | 0.51 | 0.47 | 1.29 | 2.37 | 2.64 | 3.10 | 3.67 | 4.27 | 7.99 | 7.95 | 7.55 | 5.85 |
| Depreciation | 3.05 | 3.35 | 3.90 | 4.64 | 5.06 | 5.17 | 5.59 | 7.45 | 9.27 | 9.29 | 9.02 | 10.63 |
| Profit before tax | 0.19 | 0.78 | 2.83 | 4.01 | 1.82 | 4.25 | 8.62 | 4.47 | 4.62 | 4.06 | 8.79 | 4.81 |
| Tax % | -142.11% | -16.67% | 11.66% | 21.95% | -23.08% | -4.47% | 34.11% | 50.78% | 42.64% | 37.93% | 17.18% | 135.55% |
| 0.46 | 0.91 | 2.50 | 3.12 | 2.25 | 4.44 | 5.68 | 2.20 | 2.65 | 2.53 | 7.28 | -1.71 | |
| EPS in Rs | 0.49 | 0.97 | 2.67 | 3.17 | 1.82 | 3.45 | 4.23 | 1.54 | 1.78 | 1.70 | 4.24 | -0.77 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -145% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -23% |
| 3 Years: | -7% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.35 | 9.35 | 9.35 | 9.85 | 12.35 | 12.89 | 13.42 | 14.26 | 14.90 | 14.90 | 17.16 | 22.19 |
| Reserves | -0.18 | 0.71 | 3.22 | 9.46 | 14.92 | 20.14 | 29.11 | 32.87 | 36.97 | 39.50 | 60.74 | 70.97 |
| 5.69 | 16.91 | 27.06 | 25.12 | 21.68 | 24.37 | 30.96 | 67.44 | 62.39 | 73.06 | 54.03 | 67.38 | |
| 26.57 | 18.69 | 11.49 | 15.08 | 6.37 | 6.29 | 6.03 | 7.91 | 8.77 | 9.67 | 11.30 | 17.89 | |
| Total Liabilities | 41.43 | 45.66 | 51.12 | 59.51 | 55.32 | 63.69 | 79.52 | 122.48 | 123.03 | 137.13 | 143.23 | 178.43 |
| 19.69 | 23.54 | 28.57 | 27.66 | 30.01 | 34.99 | 52.05 | 95.17 | 88.87 | 80.37 | 88.24 | 123.02 | |
| CWIP | 0.07 | 0.04 | 2.96 | 3.94 | 0.07 | 0.15 | 0.32 | 0.87 | 1.90 | 9.21 | 12.84 | 4.81 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 21.91 |
| 21.67 | 22.08 | 19.59 | 27.91 | 25.24 | 28.55 | 27.15 | 26.44 | 32.26 | 47.55 | 42.15 | 28.69 | |
| Total Assets | 41.43 | 45.66 | 51.12 | 59.51 | 55.32 | 63.69 | 79.52 | 122.48 | 123.03 | 137.13 | 143.23 | 178.43 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.25 | 8.81 | -5.66 | 11.11 | -0.78 | 8.61 | 14.18 | 16.64 | 14.83 | 15.52 | 11.83 | ||
| -2.04 | -7.20 | -11.84 | -4.72 | -3.53 | -10.23 | -22.82 | -51.11 | -4.00 | -7.95 | -15.84 | ||
| -0.89 | -0.32 | 6.83 | -3.43 | 0.72 | 2.09 | 8.78 | 35.02 | -11.18 | -7.56 | 3.90 | ||
| Net Cash Flow | -0.68 | 1.30 | -10.67 | 2.96 | -3.59 | 0.47 | 0.14 | 0.55 | -0.34 | 0.01 | -0.11 | |
| Free Cash Flow | 0.21 | 1.61 | -17.50 | 6.39 | -4.31 | -1.62 | -8.64 | -34.47 | 10.83 | 7.57 | -4.01 | |
| CFO/OP | 81% | 234% | -70% | 110% | -13% | 68% | 96% | 118% | 77% | 80% | 65% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88.43 | 48.79 | 82.03 | 91.48 | 54.98 | 69.11 | 51.39 | 85.37 | 86.52 | 94.76 | 87.98 | 80.42 |
| Inventory Days | 557.61 | 169.23 | 204.47 | 289.48 | 255.75 | 451.13 | 672.29 | 312.99 | 429.70 | 831.44 | 491.08 | 365.90 |
| Days Payable | 814.41 | 362.93 | 242.14 | 304.36 | 152.08 | 166.72 | 70.37 | 74.02 | 50.68 | 100.49 | 61.78 | 88.00 |
| Cash Conversion Cycle | -168.38 | -144.91 | 44.36 | 76.61 | 158.65 | 353.52 | 653.31 | 324.35 | 465.53 | 825.71 | 517.29 | 358.32 |
| Working Capital Days | -353.72 | -131.29 | 19.25 | -13.28 | 36.22 | 35.15 | 28.76 | 8.10 | 38.09 | 63.76 | 100.26 | -22.24 |
| ROCE % | 4.67% | 5.98% | 12.37% | 15.18% | 9.55% | 13.82% | 18.78% | 9.29% | 11.02% | 9.94% | 9.04% | 7.29% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Workforce Number of Employees ・Standalone data |
|
||||||||||
| Pre-clinical Research Facility Area Sq. Ft. ・Standalone data |
|||||||||||
| Campus Size Acres ・Standalone data |
|||||||||||
| Number of Supported Firms/Clients Count ・Standalone data |
|||||||||||
| Annual Animal Production Capacity Numbers ・Standalone data |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Jun - Newspaper advertisement - Notice of postal ballot & e-voting
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 12 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Jun - Newspaper publication of notice for special window for re-lodgement of transfer request of physical shares
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 8 Jun
-
Report On Re-Lodgement Of Transfer Requests Of Physical Shares
6 Jun - Reported nil re-lodgement requests for physical share transfers in May 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBTL is a full-service preclinical contract research organisation (CRO) and specific pathogen free (SPF) laboratory animal breeder offering drug development and discovery services to pharmaceutical and biotech companies world-wide in accordance with OECD – GLP having applicability in OECD member countries and is accredited by AAALAC International. VBTL offers services in the areas of in-vitro, in-vivo, toxicity studies, pharmacological investigations, etc.